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Abstract
Introduction:  Leg ulcers are a frequent and debilitating complication of sickle cell
disease (SCD), particularly of the SS genotype. The prevalence of leg ulcers in patients
with sickle cell disease (SCD) varies geographically ranging widely from 75% in Jamaica
to as low as 1% in Saudi Arabia. The prevalence of leg ulcers in the Cooperative Study
of Sickle Cell Disease (CSSCD) in the United States was 5% in SS genotype with the
incidence  increasing  with  age.  As  patients  with  SCD have  increasingly  improved
survival, the prevalence of leg ulcers is likely to be higher. These ulcers are slow to heal,
have a high rate of recurrence, and are associated with severe unremitting pain and
depression,  thus leading to high healthcare costs.  Despite being a well‐recognized
complication of SCD, there are no specifically designed evidence‐based guidelines to
help clinicians manage these patients.
Methods: To prepare this manuscript, we searched PubMed using the search terms
“sickle cell,” “ulcer,” “sickle cell,” and “wound.” We also appraised the references
mentioned in the identified articles. Inclusion criteria included case reports, case series,
retrospective reviews, clinical trials, randomized controlled trials, systematic reviews,
and meta‐analyses from 1945 to 2016. We present our extensive personal observations
and expert opinion, whenever there is a lack of reliable data.
Conclusion: Our understanding of the pathophysiology of leg ulceration in sickle cell
disease is improved, though still limited since the first described case in the English
literature over 100 years ago. Moreover, there remains a paucity of good quality
randomized clinical trials to test new and effective therapies. No evidence‐based
guidelines for the management of these patients are available. Currently, a holistic
multidisciplinary approach is recommended with adequate systemic control of SCD as
well as aggressive local therapy, with a focus on targeting pathways involved in
potentiating healing of these ulcers including novel approaches like topical nitric oxide
donors. SCD patients with leg ulcers represent a cohort of patients who are at an
increased risk of developing other vasculopathic complications that have a potentially
common mechanism including pulmonary hypertension, renal and retinal disease, and
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priapism. Prospective trials are needed to better evaluate the natural history of these
patients in the modern era and develop preventative and therapeutic strategies for the
management of this serious complication.
Keywords: leg ulcers, wounds, sickle cell disease
1. History
The first patient with SCD described in the English medical literature more than 100 years ago
suffered from leg ulceration [1, 2, 4–7, 9]; however, it was not until 1939 that the causal role of
SCD in leg ulceration was established [3].
2. Epidemiology
2.1. Prevalence and geographic variation
Leg ulcers are a frequent and debilitating complication of sickle cell disease, particularly of
the SS genotype. The prevalence of leg ulcers in patients with sickle cell disease (SCD) var‐
ies geographically widely ranging from 75% in Jamaica to 1% in Saudi Arabia [4–5]. In the
Cooperative Study of Sickle Cell Disease (CSSCD) in the United States, the overall preva‐
lence was 2.5%, in persons 10 years of age and older and was higher in patients with SS
disease (4.97%) and SS‐alpha thalassemia (3.92%) compared to patients with SC disease
and SS‐beta thalassemia [6]. However, over 70% of the study population was under the age
of 30 years, and along with improved survival of SCD patients, the prevalence of leg ulcers
is likely to be much higher. In a sickle cell clinic in West Indies, 58% had a history of leg
ulcers out of 102 patients who survived beyond 60 years of age [8]. About 20% of the 505
patients screened at the National Institutes of Health (NIH) recalled having had an ulcer
[9]. The incidence of leg ulcers in sickle cell patients is hard to elucidate given the lack of
any recent large prospective trials. The incidence of leg ulcers in patients with SS genotype
was 9.97/100 persons in the Cooperative Study of Sickle Cell Disease [6]. In comparison, the
prevalence of venous ulcers in the general population in the United States is approximately
600,000 annually [10] with 1% of the population is affected at any given time. Thus, the
incidence of leg ulcers in patients with SCD exceeds that of the general population by more
than tenfold and also occurs at a younger age.
The striking geographic differences in leg ulcer prevalence may be attributed in part to the
differing age structure of the studied populations; however, there does seem to be a differ‐
ence even after adjusting for age. Different SCD haplotypes differ in their clinical severity.
The Bantu haplotype usually has more severe clinical manifestations compared to others;
however, there exists a considerable variation within haplotypes as well [11]. Leg ulcers
have been reported to be more common in carriers of the CAR beta‐globin gene cluster hap‐
lotype [12]. Among patients who have the Asian haplotype, leg ulceration is rare among
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adults in both the eastern province of Saudi Arabia [5, 13] and central India [4, 14]. Though
not yet defined, environmental, socioeconomic, and genetic factors are most likely responsi‐
ble for the variations in incidence.
2.2. Age
Studies from Jamaica and personal observations indicate that leg ulcers’ first occurrence is rare
before 10 years of age, is most frequently seen between 10 and 25 years of age, and continues
to increase in frequency after 30 years [2, 4]. In the CSSCD, incidence increased sharply after
second decade of life, ranging from 14.59 to 19.17 in hemoglobin SS patients and from 7.57 to
11.13 in patients with hemoglobin SS‐alpha thalassemia [6].
3. Risk factors
3.1. Gender
Some studies found a male preponderance with the rates being 15 and 5/100 person‐years in
men and women, respectively, in the CSSCD cohort [6]. Similar patterns were observed in
Ghana [15]. However, no difference was seen in studies from Nigeria and Jamaica [4] nor in
more recent reports [12].
3.2. Hematology
3.2.1. Type of SCD
The prevalence of leg ulcers is higher in patients with SS and SS‐alpha thalassemia than among
those with SC, SB+, or SB0 genotypes. Alpha thalassemia with two alpha gene deletions seems
to be protective against development of leg ulcers in patients with sickle cell disease [6]. In
CSSCD, incidence of leg ulcers was significantly lower in SS patients with two alpha gene
deletions compared to patients with SS disease and SS patients with three alpha gene deletions.
More recent data have shown that alpha thalassemia (one gene deletion) is not protective [12].
3.2.2. Hemoglobin and hemoglobin F level
Data from CSSCD suggest that higher hemoglobin level as well as higher fetal hemoglobin
percentage is protective against development of leg ulcers in SS patients, whereas only fetal
hemoglobin is protective in SS‐ alpha thalassemia patients [6].
Incidence of leg ulcers was 43.2 events per 100 person‐years in patients with hemoglobin levels
<6 g and 2.4 events per 100 person‐years in patients with hemoglobin >12 g.
In both genotypes, the incidence of leg ulcers decreased with an increase in fetal hemoglobin.
Incidence was 0.7/100 person‐years in patients with HbF levels of >10% compared to 13/100
person‐years in patients with HbF levels of <5%. Most recent series [12, 16] did not show a
relationship between HbF and leg ulcers. Of note is that the latter study included individuals
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that received hydroxyurea (HU) therapy and whose elevated HbF levels were not constitu‐
tional, but induced by the use of this drug. Patients did not enjoy its protecting effects since
birth, as in the case of the older studies. Furthermore, hydroxyurea's other (negative) effects
on angiogenesis could have blunted the benefits of high hemoglobin F.
4. Pathogenesis
4.1. Mechanical obstruction of microcirculation
Sickle cell disease is characterized by vasoocclusion. The rigid deformed sickle cells get
entrapped in the microcirculation leading to hyperviscosity, decreased blood flow through
venules and capillaries, and chronic hemolysis resulting in anemia, ischemia‐reperfusion
injury, and inflammation causing end‐organ damage [4]. Studies have shown that the hema‐
tocrit to viscosity ratio as well as red blood cell (RBC) deformability was reduced in sickle cell
patients with leg ulcers [17, 18]. The marginal circulation of the malleoli is particularly
susceptible to this obstruction of microcirculation, making them the most common site for
sickle cell leg ulcers.
4.2. Hemolysis‐vascular dysfunction syndrome
Nitrogen oxide (NO) is a natural occurring free radical found in plasma. Receptors for NO
present on the endothelium initiate relaxation of vascular smooth muscle causing vasodilation
and increased blood flow along with reduced neutrophil adhesion. Chronic hemolysis is a
hallmark of SCD and results in red blood cell (RBC) membrane damage, cell breakdown, and
extrusion of free hemoglobin into plasma. This free hemoglobin scavenges NO, reducing its
bioavailability and thus linked to hemolysis‐vascular dysfunction syndrome which is charac‐
terized by chronic vasoconstriction contributing to leg ulcers, priapism, and pulmonary
hypertension [19, 20].
4.3. Venous incompetence
An early study of 16 SCD patients with leg ulcers using manometry and the Doppler studies
failed to demonstrate venous insufficiency as a primary factor in development of leg ulcers in
SCD [21]. However, edema and pain often precede ulceration in these patients, and numerous
studies since then have linked venous stasis with sickle cell leg ulcers [7]. Venous stasis in the
calf muscles was suggested by the delayed clearance of 99mTc [22] and by magnetic resonance
spectroscopy studies [23] in SS patients with leg ulcers as compared with those without.
Mohan et al. described reduced venous refilling time and cutaneous red blood cell flux
recovery time after exercise in patients with SS disease with leg ulcers compared to SS and AA
patients without ulcers. They proposed incompetence in venous valves around the ankle
resulting in venous hypertension and development as well as delayed healing of leg ulcers [24].
The Jamaican cohort study of 183 SS and 137 age‐ and sex‐matched AA controls showed
significant association of venous incompetence and leg ulcers in SCD. Contributing factors
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were hypothesized to include sluggish circulation with dependency, turbidity and impaired
linear flow at venous valves, hypoxia‐induced sickling, rheological effects of high white cell
counts, and activation of coagulation cascade [25]. Cummings et al. obtained similar results in
2007 with venous incompetence significantly linked to development of leg ulcers in SCD [26].
Minniti et al. used laser speckle contrast imaging (LSCI) and infrared (IR) thermography to
study regional blood flow of ulcer beds. The presence of venostasis was confirmed by their
finding of increased number of blood vessels with fibrin thrombi and vascular occlusion [16].
Cutaneous hemosiderosis, dermatosclerosis, and prominent superficial veins are frequently
found in SCD patients and further support the role of venostasis in the pathogenesis of leg
ulcers. Further clinical evidence comes from the fact that ulcers tend to worsen on prolonged
standing and improve with bed rest and compression therapy [7, 16, 25, 26].
4.4. Hypercoagulability, thrombosis, and inflammation
Ischemic injury caused by microvascular occlusion by sickle cells initiates a pro‐inflammatory
and procoagulant cascade that is initiated by the upregulation of RBC integrins. This is
Figure 1. Microscopic analysis of skin biopsies. Evidence of increase in vascularity, chronic inflammation, vasculop‐
athy with blood vessels occlusion, fibrin deposition in the intima, and microthrombi. Panel A: Scanning magnifica‐
tion view of the skin punch biopsy showing edge of an ulcer from the right ankle of patient MD. The epidermal
changes adjacent to the ulcer are characterized by acanthosis, hyperkeratosis, and attenuated rete ridges. There are in‐
creased vascularity and inflammation in the dermis (H&E, 100× original magnification). Panel B: The histological
changes subjacent to the ulcer bed are characterized by chronically inflamed granulation tissue with vasculopathic
changes involving some of the small blood vessels (H&E, 200× original magnification). Panel C: High magnification
view of the superficial dermal vessels peripheral to the ulcer shows proliferation of thick‐walled capillaries and ven‐
ules, consistent with chronic stasis. There is a lymphoplasmacytic inflammatory infiltrate in the dermis (H&E, 400×
original magnification). Panels D–F: Very high magnification view of involved vessels subjacent to the ulcer bed reveals
eosinophilic fibrin deposits within the vessel wall and partial occlusion of the vascular lumen (H&E, 600× original
magnification). Panel G: Scanning magnification view of the skin punch biopsy obtained from the right dorsal foot of
patient DD shows vasculopathic changes involving a cluster of small blood vessel in the deep dermis (H&E, 40× origi‐
nal magnification). Panel H: High magnification view of the involved vessels reveals eosinophilic fibrin deposits within
the vessel wall associated with intimal hyperplasia and narrowing of the vascular lumen (H&E, 400× original magnifi‐
cation). Reproduced with permission from Minniti et al. [16].
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followed by RBC adhesion to the endothelium, platelet aggregation, and granulocyte recruit‐
ment with the release of pro‐inflammatory cytokines [27]. The cycle of vessel obstruction and
ischemic injury is hence perpetuated, culminating in further end‐organ damage. Minniti et al.
provided histopathologic evidence of vasculopathy characterized by mural fibrin thrombi
causing luminal narrowing and progressive vascular occlusion in small vessels in ulcer beds
of SCD patients with leg ulcers [16] (Figure 1). Earlier studies also alluded to the procoagulant
state in SCD patients including elevated levels of factor VIII and low levels of antithrombin III
and prothrombin complexes [28, 29]. SCD ulcer patients have higher levels of soluble ICAM‐
1 and the key inflammatory cytokine IL‐1 beta [30]. Oxidative stress has been shown to play a
role in leg ulcer pathogenesis in sickle cell patients, and patients with glutathione S‐transferase
polymorphism (GSTM1 and GSTT1 null phenotypes) have been shown to have a high risk of
developing ulcers [31].
4.5. Autonomic dysfunction
Cardiac output is increased in patients with SS disease, and this may affect the distribution
of peripheral blood flow and reflex vascular responses [4]. Normal microcirculation of the
lower extremity (LE) is characterized by the venoarteriolar vasoconstriction reflex and the
disappearance of vasomotion in the dependent position. It was noted that the venoarteriolar
reflex was abolished and vasomotion preserved in the dependent position of the leg in SCD
patients [32]. In addition to a high resting perfusion in patients with SCD to maintain nor‐
mal integrity of cutaneous tissue, there occurs a pronounced vasoconstriction on dependen‐
cy that exacerbates ischemia and pain, delays healing, and promotes recurrence of leg ulcers
[7, 33].
4.6. Bacterial colonization
The role of bacteria in the pathogenesis of leg ulcers is uncertain. Secondary bacterial coloni‐
zation is inevitable and usually not considered to be clinically significant. Commonly isolated
bacteria in African reports include Staphylococcus aureus, beta‐hemolytic Streptococci, Pseudo‐
monas aeruginosa, and Salmonella. Anaerobes comprised >50% of isolated bacteria in an African
series, whereas bacterial flora is predominantly aerobic and polymicrobial in Jamaican reports.
Bacterial colonization although unlikely to initiate ulceration may contribute to persistent
inflammation of surrounding tissue that results in delayed healing [7]. Baum et al. reported
improved healing with topical antibiotics; however, this carries the risks of bacterial resistance,
contact sensitization, and disruption of wound moisture balance [7]. Researchers no longer
rely solely on culture for identification of bacteria and are utilizing sophisticated sequencing
techniques to elucidate the full diversity of microbial communities on the human body [34].
The ulcer skin microbiome, which has been thought only as a commensal on healthy skin, can
contribute to delayed healing of ulcers in patients with sickle cell disease by causing excessive
activation of both the innate and adaptive immune systems [35]. Emerging data from the study
of diabetic wounds shows that the diversity of the skin microbiome correlates with ulcer
characteristics [36], and it is likely that similar mechanisms are at play in sickle cell leg ulcers
that may explain the variability in their occurrence.
Sickle Cell Disease - Pain and Common Chronic Complications176
4.7. Genetic factors
Studies suggest that the expression of certain genes may contribute to the development of leg
ulcers in SCD; however, the data on genetic associations with leg ulcers remains limited [12].
4.7.1. Candidate gene studies
Ofusu et al. published a study of 9 cases and 29 controls in 1987 suggesting a possible
association of HLA‐B35 and CW14 alleles, with carriers of both alleles having a 17‐fold
increased risk of developing leg ulcers. This study was limited due to its small size as well as
the identified region being hard to study due to long‐range disequilibrium [12, 37].
Another candidate gene study of 243 cases and 516 controls from the CSSCD by Nolan et al.
identified associations with single nucleotide polymorphisms (SNPs) in Klotho (promotes
endothelial NO production), TEK (involved in angiogenesis), and numerous genes in the
transforming growth factor‐β (TGF‐β)/BMP pathway (modulates angiogenesis and wound
healing) [38].
Some of the same SNPs have been reported to be associated with risk of stroke, pulmonary
hypertension, and priapism, further supporting the observation that leg ulcers are often
associated with other sickle cell sub‐phenotypes [12].
4.7.2. Genome‐wide association studies
Preliminary results from genome‐wide association studies of 219 cases and 1180 controls from
the CSSCD identified 30 SNPs associated with leg ulcer. It also showed that a cluster of genes
in the MHC III region of chromosome 6 to be highly associated with leg ulcers [12]. A cross‐
sectional study identified that an SNP in IL‐6, a pro‐inflammatory cytokine, was associated
with higher likelihood of leg ulcer and retinopathy [39].
Figure 2. Proposed simplified mechanism of sickle cell ulcer pathogenesis. Reproduced and modified with permission
from Minniti et al. [2].
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4.7.3. Summary
Minniti and Kato proposed a stepwise, multifactorial model for SCD ulcer pathogenesis (see
Figure 2) that depicts an interplay between poor nutrition, low BMI, skin injury, inflammation,
thrombosis, hemolysis, vasculopathy, neuropathy, and poor socioeconomic status [2, 9, 16, 29,
33, 40].
5. Characteristics of ulceration
5.1. Mode and age of onset
Ulcer onset can be traumatic or spontaneous. Trauma accounts for approximately half the
cases, which are incited by relatively insignificant physical damage such as scratches, abra‐
sions, and animal or insect bites. In spontaneous ulcers, there is no history of trauma, but a
lesion develops within the dermis often with surrounding induration and hyperpigmentation
[7]. Initially, lesions may be covered by an intact epidermis, which then breaks down forming
small, deep, and painful ulcers. Spontaneous ulcers are thought to originate from skin
infarction. Ulcers occur initially in the second decade of life, around 18–20 years of age. The
occurrence of a de novo ulcer in older patients is not common, unless the patient had an ulcer
before.
5.2. Site
Leg ulcers most frequently affect the skin around the medial or lateral malleoli but can also
occur on the anterior shin or dorsum of the foot [4] and occasionally in the digits [Minniti,
personal observation]. The predilection for the malleoli is likely multifactorial due to marginal
blood flow at the site, high venous pressure, less subcutaneous fat, thin skin, and lymphedema
[12, 27]. This is similar to other hematologic conditions including hereditary spherocytosis,
β‐thalassemia intermedia, and Felty's syndrome. While medial involvement was more
common in two studies [41, 42], there was no such difference found for the medial, lateral, left,
or right legs in the CSSCD [6].
5.3. Size
In the CSSCD, ulcers ranged between 0.5, 5–10, 10–15, and >15 cm with equal frequency. Most
Jamaican studies had ulcers <10 cm in size. However, large circumferential ulcers portend a
poor prognosis due to inevitable damage to vessels and lymphatics [4]. Pain is not related to
wound size, and often initial, small ulcers are extremely painful (see Figure 3). Purulence, poor
granulation tissue, and nonhealing are frequently reported in ulcers >10 cm.
5.4. Appearance
Ulcers in individuals with sickle cell disease usually have a punched appearance with well‐
defined margins and slightly raised edges. The base comprises granulation tissue, often
Sickle Cell Disease - Pain and Common Chronic Complications178
covered by yellow slough. More than half of patients will have more than two ulcers that
are present at the same time, and multiple small ulcers may then coalesce to form a large
ulcer.
Histology of an early leg ulcer shows neovascularization, chronic inflammation, vasculopathy
with blood vessel occlusion, fibrin deposition in the intima, and microthrombi [16] (see
Figure 1). The epidermis adjacent to the ulcer reveals acanthosis, hyperkeratosis, and attenu‐
ated rete ridges. There is increased vascularity and inflammation in the dermis with a lym‐
phoplasmacytic inflammatory infiltrate. Chronically inflamed granulation tissue with
vasculopathic changes in small blood vessels is found subjacent to the ulcer bed [2, 4].
5.5. Staging and severity of leg ulcers
Ulcers may be staged according to their depth as follows [12]:
Stage 1: Nonblanchable erythema of intact skin, which may present as skin discoloration,
warmth, edema, or induration in darker skinned patients.
Stage 2: Partial‐thickness skin loss involving epidermis, dermis, or both, presenting as an
abrasion, blister, or shallow crater.
Stage 3: Full‐thickness skin loss involving damage to or necrosis of subcutaneous tissue that
may extend down to, but not through, underlying fascia. The ulcer presents clinically as a deep
crater with or without undermining of adjacent tissue.
Stage 4: Full‐thickness skin loss with extensive tissue destruction or damage to muscle, bone,
or supporting structures (tendon, joint capsule).
Figure 3. Large sickle cell leg ulcers associated with foot deformities (from author's personal collection).
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5.6. Healing and recurrence
Leg ulcers can be classified as acute or chronic although there is no consensus as to a specific
length of time to define chronicity. An acute ulcer usually heals in less than a month. Chronic
ulcers usually persist for at least 6 months and may last for several years. As described above,
ulcer healing is typically slow as the ulcer fills in with granulation tissue, and a bluish
epithelium may be seen growing in from the ulcer margin. Healing rates of 3.3–8.1 mm2/d
have been reported in SS disease [43, 44] compared with rates of 400 mm2/d in other types of
leg ulcer [45]. Even after satisfactory healing, 25–52% recurred in the CSSCD [6]. It is generally
accepted, and it is the author's experience that if an ulcer does not heal within 6 months, its
chances of ever healing are slim.
Minniti et al. have proposed three patterns of leg ulcers in SCD [2]:
• One‐time ulcer
One half of patients with SCDs will develop only one ulcer in their lifetime. It usually occurs
in the second decade of life, heals within several months, and may recur during periods of
stress. These patients often have infrequent pain crisis and have renal and pulmonary com‐
plications.
• Stuttering ulcer
Twenty‐five percent of SCD patients develop small ulcers that recur every 6–12 months for
several years.
• Chronic, recurrent ulcer
Approximately 1% SCD patients in the United States develop an ulcer that persists for years
or even decades and/or ulcers that recur in the same or nearby sites. These patients experience
the most disabling chronic pain, unemployment, and depression. Amputation may need to be
considered in rare cases to improve quality of life [2, 46]. These patients are often tall, under‐
nourished, and severely anemic with high hemolytic rate. They may have nephropathy, have
rare vasoocclusive crisis, and often have trouble with employment, social interaction, and
depression.
6. Diagnosis
6.1. History
Leg ulcer pain may be severe, excruciating, penetrating, sharp, and stinging. Patients often
report a crescendo of localized pain just before new ulcers develop [2]. About 40–50% of
patients recall prior trauma [15, 16], often trivial or pruritus that incites scratching and skin
breakdown. The pain is often exacerbated by exposure to cold and to air. The size of the ulcer
does not necessarily correlate with intensity of the pain, and very small ulcerations can be
extremely painful as well. Most patients require opioids for pain control.
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Patients should be specifically asked about history of ulcers, since many patients will report
having leg ulcers at some point in their lifetime and may not volunteer the information
themselves. History should also document prior ulcer therapies and other complications
associated with leg ulcers in SCD including pulmonary hypertension, stroke, priapism, acute
chest syndrome [38, 45], lower extremity venous thrombosis, and retinopathy [2].
6.2. Physical examination
Physical exam should assess the wound size with ruler measurement as well as digital
photography for greater accuracy [47]. Surrounding skin hypo‐ or hyperpigmentation, edema,
and muscle atrophy should be noted. Although serous discharge and fibrinous material are
common, periwound erythema, purulent discharge, and worsening pain may be signs of acute
infection. Inguinal lymph nodes are often enlarged, especially during ulcer exacerbations and
do not necessarily signify infection. Pulse oximetry as well as blood pressure may be low.
Attention should be paid to the nutritional status of patients as many are malnourished [2].
6.3. Lab testing and imaging
Sickle cell individuals with ulcers often have infrequent pain crises and may not have sought
regular medical care prior to their presentation. Occasionally, this will be the first time a
physician has evaluated them for end‐organ diseases. Complete blood count and chemistry
panel often reveal markers of severe chronic hemolysis. A significant increase in LDH may be
seen [48]. Urinalysis may show microalbuminuria. Serum C‐reactive protein (CRP) and
erythrocyte sedimentation rate (ESR) are often elevated. Patients may have low levels of
antithrombin III, protein C or S, high level of factor VIII, or positive lupus anticoagulant.
Wound cultures usually reveal only superficial colonizing bacteria and are rarely helpful.
Nutritional status and exercise tolerance with 6‐minute walk test (6MWT) should be recorded.
When interpreting 6MWT, be aware that shorter distances secondary to physical impairment
and pain can be caused by the ulcer. Echocardiography should be obtained to evaluate
tricuspid regurgitant velocity to screen for pulmonary hypertension. Imaging studies of bones
commonly show demineralization and bone infarcts. MRI should be obtained when osteo‐
myelitis is suspected, but the gold standard for diagnosis remains bone biopsy. Osteomyelitis
in the underlying bone is a rare occurrence, but if not diagnosed and treated appropriately will
prevent healing [2]. A Doppler ultrasound of the lower extremities should be obtained to rule
out the presence of a DVT.
7. Treatment
The management of leg ulcers in SCD involves a multipronged and multidisciplinary approach
(see Table 1) with involvement of the primary hematologist, wound care specialist, nutritionist,
surgeon, and social worker [2]. There remains a paucity of data from randomized controlled
trials to guide treatment [49]. Current practice relies mostly on data from small case reports
and case series along with expert opinion.
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Local therapies Systemic therapies
Topical antibiotics Zinc sulfate
Skin grafts (autologous or bioengineered) Pentoxifylline
RGD peptide matrix l‐Carnitine
Moist wound dressing Arginine butyrate
Growth factors Endothelin antagonists: bosentan
Medical honey Hydroxyurea
Allogeneic keratinocytes Red blood cell transfusions
Collagen matrix Systemic antibiotics
Autologous or allogeneic platelet gel Hyperbaric oxygen therapy
Synthetic heparan sulfate
Topical sodium nitrite
Energy‐based modalities
Negative‐pressure wound therapy
Leg compression and leg elevation
Topical analgesics
MIST™
Transdermal oxygen
Maggots
Surgical debridement
Table 1. Treatment modalities that have been used in patients with sickle cell disease and leg ulcers.
7.1. Topial treatment
7.1.1. Role of topical antibiotics
A randomized controlled trial of a topical antibiotic preparation (neomycin, bacitracin, and
polymyxin B) in 30 patients with SS disease and chronic leg ulceration showed a significant
reduction in ulcer size over a period of 8 weeks in the treatment group compared to the control
group [50]. However, this trial had a high risk of bias, and the majority of the literature since
1987 questions the role of bacterial infections in wound pathogenesis [7, 51].
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7.1.2. Type of dressing
La Grenade et al. conducted a randomized controlled trial, in 32 patients with SS disease, of
Solcoseryl®, DuoDerm®, and conventional therapy, cleaning with Eusol® (a mild antisep‐
tic) followed by wet dressing. Patients were randomized to one of three therapies and moni‐
tored for 12 weeks. DuoDerm® (ConvaTec, Greensboro, NC) hydrocolloid dressing was
generally unacceptable, and two‐thirds of the patients defaulted from this treatment. Solco‐
seryl®, a deproteinized extract from calf's blood that is meant to improve the tissue utiliza‐
tion of oxygen, increased ulcer healing compared to the controls, but the difference was not
significant [52].
7.1.3. RGD peptide matrix
A 2014 Cochrane review described single trial that used an arginine‐glycine‐aspartic acid
matrix (RGD peptide matrix) that achieved noticeable benefit in the treatment of leg ulcers in
SCD. The RGD peptide matrix is believed to act as a synthetic extracellular matrix to promote
cell migration, keratinocyte layer formation, and wound strengthening. Chronic ulcers treated
with RGD peptide matrix had a statistically significant decrease in surface area; however,
further studies are needed to corroborate these findings [51, 53].
7.1.4. Moist wound‐healing approach
A small retrospective cohort study underscored the efficacy of simple moist wound‐healing
approach in patients with chronic leg ulcers in SCD who had failed to heal despite treatments
such as debridement, split‐thickness skin grafts, muscle flaps, wet‐to‐dry dressings, Unna
boots, hydroxyurea, recombinant human erythropoietin, and arginine butyrate. Ultimately, all
patients were treated with topical hydrocolloid dressing (DuoDerm CGF by ConvaTec). The
eight patients who had not received surgical treatment healed completely within 2–16 months,
with only one recurrence at 4 months. Of the ten patients who had previous surgical treatment,
six healed without recurrence at 30 months, two experienced recurrence with resolution upon
the reapplication of DuoDerm, and two did not heal though did not experience worsening of
their ulcers [2, 54].
7.1.5. Growth factors
Several case reports have used topical growth factors as an approach to treating leg ul‐
cers.
Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) has been used topically and via
intracutaneous injection [55, 56]. The cytokine activates macrophages and induces the prolif‐
eration of keratinocytes and differentiation of myofibroblasts. While it was shown to be
beneficial in wound healing [55–58], high cost, severe vasoocclusive, and even fatal events have
discouraged its use [58].
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7.1.6. Use of skin substitutes
There are several skin substitutes that are available commercially. One of them, Apligraf®
(Organogenesis, Canton, MA), is a bi‐layered bioengineered skin substitute that has been
approved by the Food and Drug Administration (FDA) since 2000 for the treatment of diabetic
foot ulcers and venous leg ulcers (VLUs) that have not responded within 4 weeks to standard
of care (SOC) therapy [7]. Apligraf provides both cells and matrix for the nonhealing wound
possibly via production of cytokines and growth factors similar to healthy human skin [59].
Several studies confirm the efficacy of Apligraf in treatment of VLUs, and the Society of
Vascular Surgery approves the use of Apligraf for the treatment of VLUs [57, 60–62]. The
optimal frequency of use is not known, and current clinical practice is for consideration of
reapplication after at least 1–3 weeks of observation after initial application [7].
Gordon and Bui examined the efficacy of Apligraf in their study of sickle cell patients with
chronic ulcers. Prior to application, they used a 4‐week regimen of hydrogel, followed by 1
week of wet‐to‐dry dressings and 1 week of wet‐to‐dry dressings plus application of papain‐
urea debriding ointment (Accuzyme). After 6 weeks, the ulcer was sufficiently optimized for
closure. The use of Apligraf resulted in complete healing, and the ulcer remained healed at the
last follow‐up (33 months) [63].
7.1.7. Allogeneic keratinocytes
Allogeneic keratinocytes have been used to promote the migration of autologous kerati‐
nocytes from the peripheral wound bed. Sheets of cells applied twice per month success‐
fully healed a chronic ulcer within 3 months, without recurrence at follow‐up at 8 months
[64].
7.1.8. Collagen matrix
Two patients with chronic ulcers were treated with Collistat (collagen matrix) every 4 weeks
and experienced complete healing by 10 and 12 weeks [65].
7.1.9. Autologous platelet gel
A case series reported the use of an autologous platelet gel to treat leg ulcers in five SCD
patients. Autologous platelet‐enriched plasma was applied to the wound margins and fibrin
matrix clot to the wound bed, before covering with moist saline gauze. A significant local
release of platelet‐derived growth factors (PDGFs), transforming growth factor‐β (TGF‐β), and
vascular endothelial growth factor (VEGF) was noted. Three of the patients showed a reduction
of the leg ulcer area by 85.7–100% within 6–10 weeks. Two patients with ulcers threefold to
tenfold larger experienced 20.5% and 35.2% decreases in the leg ulcer area. The authors
concluded that the use of autologous platelet gel offers a promising and cost‐effective adjuvant
treatment for leg ulcers particularly in small ones [66].
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7.1.10. Synthetic heparan sulfate
A synthetic, bioengineered heparan sulfate solution, Cacipliq20, was used to treat a nonhealing
leg ulcer. The solution is designed to function as a glycosaminoglycan mimetic, potentially
restoring the extracellular matrix scaffold and enhancing growth factor recruitment to aid in
collagen production and angiogenesis and to restore tissue homeostasis and protect the wound
from further damage. The patient in this case report had failed to respond to several treatments,
including moist wound therapy, grafting, and energy‐based modalities. The patient experi‐
enced complete healing after 8 weeks of twice‐weekly applications [67].
7.1.11. Topical nitrite therapy
A phase 1 trial of escalating doses of topical sodium nitrite demonstrated a dose‐dependent
improvement in ulcer healing and decreasing pain at the ulcer site [68]. Application of topical
sodium nitrite twice weekly for 4 weeks was associated with a significant increase in peri‐
wound cutaneous blood flow measured by laser speckle contrast imaging. It appeared to be
well tolerated with no grade 3–4 adverse events. The authors concluded that topical sodium
nitrite 2% cream is suitable for additional clinical trials in adults with sickle cell anemia to
promote healing of leg ulcers.
7.1.12. Topical honey
Topical honey has been utilized mostly in burns and postoperative wounds as a dressing
providing a moist healing environment in addition to its natural anti‐inflammatory, healing,
and antibacterial properties [69]. Its use has also been described in the sickle cell literature for
treatment of leg ulcers [15].
7.1.13. Energy‐based modalities
Low‐frequency, noncontact ultrasound (e.g., MIST®) has been employed to accelerate healing
of sickle cell ulcers. It is believed to act via effective removal of bacteria and biofilm along with
reduction of chronic inflammation. It also appears to promote the release of NO and growth
factors at the cellular level, thereby stimulating vasodilation, angiogenesis, and collagen
deposition. This modality can also be used to optimally prepare the wound for grafting [70].
Low‐level laser therapy has been reported to result in 80% reduction in the area of a leg ulcer
after just five 10–15‐minute sessions, leading to a marked improvement in the patient's quality
of life [71]. Low‐level laser therapy has previously been reported to modulate wound healing
by increasing mitotic activity, fibroblast production, collagen synthesis, and angiogenesis and
may have a role in the apoptotic processes of wound healing [72].
7.1.14. Negative‐pressure wound therapy
Paggiaro et al. examined the use of negative‐pressure wound therapy (NPWT) in leg ulcers.
Following surgical debridement and before grafting, three wounds were treated by different
methods: a rayon and normal saline solution dressing, calcium alginate and gauze, and
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negative‐pressure therapy. Researchers found that the NPWT‐treated wounds had a more
homogenous surface with better vascularization in comparison with the other two groups. All
three wounds received a split‐thickness skin graft. While the other wounds experienced
subsequent graft failure, the NPWT‐treated wound did not, and the ulcers had not recurred
by the time of follow‐up (11 months) [73]. However, the painful nature of leg ulcers in SCD
may be a limiting factor in the use of NPWT.
7.1.15. Role of leg compression
Bed rest has been shown to promote ulcer healing. Patients who underwent 2–3 weeks of strict
bed rest experienced complete closure of their wounds within 2–3 months. In addition to
reducing venous back pressure and edema around the ankle, patients developed improvement
in RBC deformability, possibly secondary to decreased plasma volume, which also aided
healing [74]. However, this approach is not very practical.
The use of compression devices has been shown to be effective in reducing edema and
improves healing in other types of ulcers. Although there are no prospective studies evaluating
their role in sickle cell‐related ulcers specifically, these were universally recommended in a
survey of care providers treating these patients [75, 76]. The use of Unna boots is highly
recommended by practitioners, as the zinc oxide‐impregnated boots are useful in treating
lower extremity lesions exacerbated by venous insufficiency. Multicomponent compression
systems have been shown to be the most effective in reducing edema and improving venous
reflux [20].
As venous insufficiency is often seen in SCD patients, the clinical practice guidelines of the
Society for Vascular Surgery and the American Venous Forum are also applicable for treat‐
ment of leg ulcers in sickle cell with venous disease. The guidelines recommend compres‐
sion therapy to increase VLU healing and to decrease the risk of ulcer recurrence. The use
of multicomponent compression bandages is encouraged over single‐component bandages
[62].
7.1.16. Topical analgesics
Topical opioids have been employed by dissolving oxycodone and meperidine tablets in water
and applying them locally to provide topical analgesia. Total pain relief was reported likely
because of modification of peripheral opioid receptors [77]. While this treatment is not
commercially available, these findings warrant further research. Data in mice with SCD show
that topical opioids such as morphine and fentanyl not only treat pain but also hasten healing
[78]. Inhibition of neurogenic inflammation by topical opioids is advocated as the mechanism
of action. A study of nitroglycerin applied above the ulcer demonstrated a significant reduction
in ulcer‐associated pain, with increased ability to be able to manipulate the ulcer. Pain in fact
is often so intense that bedside debridement is not possible, thus ultimately delaying ulcer
healing.
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7.1.17. Hyperbaric oxygen therapy
Hyperbaric oxygen therapy and its potential benefit in treatment of vasoocclusive crises and
leg ulcers have been described in several case reports [76, 79, 80]. However, paucity of research,
potential adverse side effects, lack of treatment protocols, limited availability, and economic
factors restrict its use [7].
7.1.18. Transdermal continuous oxygen therapy
A case report described the use of transdermal continuous oxygen therapy using a portable
device that delivers oxygen directly to the wound site. Two LE wounds received treatment for
15 weeks, and the authors noted that both healed without recurrence in the 42‐month follow‐
up. The authors urge further studies utilizing this form of therapy [81].
7.1.19. Maggot therapy
Maggot therapy has had mixed results when studied in other types of ulcers. One study
showed reduced time to debridement, but increased ulcer pain and no improvement in rate
of healing [82]. In diabetic ulcers, maggot debridement provided outcomes equal to conven‐
tional surgical treatment [83]. At the NIH Clinical Center, Medical Maggots™ (disinfected
Phaenicia sericata larvae; http://www.monarchlabs.com) has been utilized. Four patients with
sickle cell disease received this therapy with mixed results. There was temporary improvement
in ulcer appearance, quickly followed by relapse and unclear long‐term benefit [7, 16]. Pain
has also been a limiting factor for the use of medicinal maggots in this population, and an
opioid PCA may be required. This modality is currently reserved only for patients who are
poor candidates for surgical debridement [76].
7.2. Systemic treatment
7.2.1. Zinc supplementation
Zinc supplementation has long been believed to promote healing in chronic wounds accom‐
panied by serum zinc deficiency [84]. A placebo‐controlled trial reported that 220 mg of zinc
sulfate administered orally three times a day significantly improved the healing of leg ulcers
in sickle cell patients [43]. However, no further studies have been undertaken to confirm these
results, and the results are hard to interpret as neither the length of supplementation with oral
zinc or statistical analysis was provided [7].
7.2.2. Pentoxifylline
Pentoxifylline improves RBC and leukocyte deformability potentially decreasing blood
viscosity, platelet aggregation, thrombus formation, and plasma fibrinogen levels [7]. This
increases microcirculatory flow and tissue oxygenation making it a good modality for
treatment of leg ulcers in sickle cell patients. One case report presented that 400 mg of oral
pentoxifylline three times a day helped completely heal a leg ulcer in a sickle cell patient within
3 months [85]. In nine RCTs involving 572 patients, pentoxifylline combined with compression
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bandages improved ulcer healing [86, 87]. The 2014 clinical practice guidelines of the Society
for Vascular Surgery and the American Venous Forum recommend the use of pentoxifylline
for treatment of long‐standing or large VLUs [62]. As venous insufficiency is often present in
SCD patients, pentoxifylline may be a good treatment option for them.
7.2.3. l‐Carnitine
Systemic therapy of leg ulcers in SCD with l‐carnitine has been reported in only one random‐
ized controlled trial and one case study. Data suggests that oral carnitine alters cellular
chemistry to favor more efficient oxidative metabolism despite reduced levels of available
tissue oxygen. The studies were limited by the fact that transfusion therapy was given
concomitantly making it difficult to draw conclusions on the effect of l‐carnitine alone [88, 89].
7.2.4. Arginine butyrate
Arginine stimulates collagen production, improves immune function, and prevents vascular
restenosis. Butyrate can stimulate PDGF production and downregulate inflammatory cyto‐
kines and enzymes that slow wound healing like TGF‐β, tumor necrosis factor‐alpha (TNF‐
α), and matrix metalloproteinases [90]. A phase II controlled trial showed significant
improvement in ulcer healing in the treatment arm after 3 months (78% vs. 24% in controls, P
< 0.001). A limitation to this approach is the requirement of an IV catheter. Larger studies are
needed to validate this potentially effective treatment modality.
7.2.5. Bosentan
A case report described complete healing of a leg ulcer in a patient with concomitant pulmo‐
nary hypertension. The ulcer had previously failed multiple therapies. The researchers
attributed the healing to the blockade of the endothelin‐1 receptor and vasodilation in the
patient with likely decreased NO availability [91]. However, concomitant transfusion therapy
might have confounded the observations.
7.2.6. Hydroxyurea
The role of hydroxyurea (HU) in the development or in the treatment of leg ulcers in sickle cell
patients is not clear with conflicting data to date [92–97]. HU increases fetal hemoglobin levels,
decreasing the intracellular polymerization of HbS, the incidence of painful crises, and the
need for transfusions in SCD patients [98]. Moreover, HU is a known NO donor and decreases
WBC counts [99]. These effects should theoretically decrease the incidence of leg ulcers.
However, leg ulcers observed in patients with chronic myeloproliferative disorders on HU
often resolved several months after the discontinuation of this medication [100–103]. A case
report suggested that HU causes an acquired blood dyscrasia that increases the risk of
ulceration [104]. Other multicenter studies have seen no evidence of an association between
hydroxyurea and leg ulceration [76]. There are no prospective trials that specifically address
the effects of HU use on leg ulcer healing in the sickle cell population, and therefore, we
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discourage reflexively stopping HU in patients with leg ulcers who may be benefiting from it
for other SCD complications like frequent pain crisis and acute chest syndrome.
7.2.7. Blood transfusions
There are no prospective RCTs addressing the role of blood transfusions for treatment of
leg ulcers in sickle cell patients. Transfusions increase the oxygen delivery to tissues by
increasing total hemoglobin and decreasing the HbS concentration [76]. Some authors sug‐
gest target hemoglobin of 10 g/dl for successful surgical treatment, although a level be‐
tween 8 and 9 g/dl may be more realistic and adequate for wound healing [20]. However,
transfusions come with their own risks including iron overload, alloimmunization, and
risk of transfusion reactions and infections. In recent clinical trials and in our clinical
practice, we note that there are patients with chronic wounds who are treated with chron‐
ic transfusions, either for other indications or because of the ulcer, with no apparent bene‐
fit in decreasing the length of ulceration. The author recommends supporting skin grafts
with transfusions for a limited time period, 4–6 months, in order to maximize graft suc‐
cess and decrease SCD‐related complications.
7.2.8. Antibiotics
As discussed above, bacterial colonization of leg ulcers appears to be common but of uncertain
clinical significance. However, colonization may lead to infection or a chronic inflammation,
and systemic antimicrobials with anti‐inflammatory properties like doxycycline, clindamycin,
and metronidazole may improve ulcer healing along with adequate debridement [20].
7.3. Surgical treatment
Surgical treatments for leg ulcers often have high rates of failure and recurrence [7]. Scar tissue
becomes denser and less vascular with each subsequent graft, shortening the ulcer‐free interval
between recurrences [7, 105]. Microsurgical free flap transfers are popular since they include
their own blood supply, which is a favorable attribute in these poorly vascular regions [106].
However, they are often limited by complications like thrombi, microemboli, and infection
ultimately requiring debridement and split‐thickness skin grafts [7].
Aiming to reduce the incidence of graft failure, some experts recommend perioperative and
even chronic lifelong transfusions to decrease HbS levels to <30% [106, 107]. Some surgeons
support the use of anticoagulation with heparin and/or aspirin, antibiotics, and the rinsing of
flaps with heparinized solution prior to attachment [106]. Larger RCTs are required to address
these important issues.
8. Nutrition
Nutrition is known to be important in the management of ulcers, and patients should be
assessed for nutritional deficiencies and treated appropriately. Zinc deficiency has been shown
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to be prevalent in SCD patients. The current recommendation is 220 mg of zinc sulfate thrice
a day. Serum zinc levels should be remeasured 2 and 4 weeks after initiation of supplementa‐
tion and therapy discontinued if levels normalize [7, 108]. Others and we have noted that the
BMI of SCD patients with recurrent ulcers is lower than patients without leg ulcers [12, Ballas,
unpublished data]. We have also noted that several of the most affected patients seem to be
almost anorexic, and we speculate that the high state of inflammation that their ulcer causes
could be responsible for the presence of TNF‐alpha, similar to cancer patients.
9. Thrombosis
Assessment and treatment of occult deep venous thrombosis are essential. Anticoagulation
may be necessary to treat known hypercoagulable disorder.
10. Pain control
The pain from leg ulcers in patients with sickle cell disease can be very severe and debilitating
leading many patients to require therapy with chronic opioids. Moreover, severe pain may
interfere with local therapies and further hinder healing. Nonsteroidal anti‐inflammatory
agents are often inadequate for optimal pain control. Currently, there are no guidelines
recommending topical analgesics in this patient population, but provocative data in sickle cell
mice suggest that the application of topical opioids can treat both the pain and increase healing
rates [78] although they should be explored in future studies. Some experts recommend
regional nerve blocks with good results in pain control and also for secondary vasodilation via
reduction of stress‐related catecholamine release. This approach is limited by the need for an
indwelling catheter, the need for frequent clinic visit for pump refills, and the antecedent risks
of infection [7].
11. Wound care
Leg ulcers in SCD are often resistant to treatment and have a high rate of recurrence, making
optimizing the wound bed a cornerstone of therapy. The ulcer must be adequately debrided
to remove biofilm and necrotic, nonviable tissue from the base and edge of the wound in order
to begin the healing process [109]. Various types of debridement techniques may be used
including autolytic, enzymatic, biological, mechanical, and sharp, depending on its suitability
to the patient, the type of wound, its location, and the extent of debridement required [110].
Regular weekly chronic debridements may be needed for improved healing although the
optimal frequency is not established [111]. Sharp debridement can be very painful and may
only be possible with some form of analgesia, topical, injectable, or general anesthesia.
Although a multitude of dressings exist, the most important principle of wound care remains
maintenance of a moist healing environment. Energy‐based modalities like low‐frequency,
Sickle Cell Disease - Pain and Common Chronic Complications190
noncontact ultrasound, electrical stimulation, and ultraviolet‐C light are good adjuvant
treatment options for wounds that fail to respond positively to standard of care methods [7].
The use of RGD peptide matrix, allogeneic keratinocytes, and autologous platelet gel are
promising treatments for resistant ulcers, although more research is needed. These are not
widely available as yet.
12. Venous insufficiency
Compression therapy is encouraged for the management and prevention of edema, especially
if venous insufficiency is present. Compression stockings are useful for prevention, while
multilayer compression bandaging is recommended for treatment. An alternative is using a
self‐applicable and adjustable short‐stretch Velcro band [62].
The Society for Vascular Surgery and the American Venous Forum strongly advocate pentox‐
ifylline for treatment of long‐standing or large VLUs since venous insufficiency is frequently
found in these patients. Apligraf is recommended for ulcers not responding to standard of care
therapies within 4–6 weeks.
Minimally, invasive ablation of superficial axial and perforator vein reflux in patients with
active venous insufficiency and patent deep venous system is a relatively safe procedure and
leads to faster healing and decreased ulcer recurrence when combined with compression
therapy [112]. This also underscores prompt referral to a vascular specialist for evaluation and
management of leg ulcers in SCD.
13. Antibiotic therapy
The IDSA guidelines do not recommend treating an uninfected wound with antimicrobials
since there is no evidence that this prevents infection or improves ulcer healing [113]. When
there are clinical signs of infection, post‐debridement deep soft tissue or bone biopsy should
be sent for culture. Superficial wound cultures are less reliable than tissue biopsies and should
be avoided [114]. Hospitalized patients with more severe infections and signs of cellulitis and/
or osteomyelitis typically receive intravenous antibiotic therapy at least initially. Finally, topical
antibiotics do not significantly affect leg ulcers healing [7]. Further studies are needed to
explore the immunomodulatory and anti‐inflammatory actions of tetracyclines on ulcer
healing.
14. Prevention
A previous history of leg ulcer is the greatest predictor of developing another leg ulcer in
patients with sickle cell disease, increasing the risk up to 23‐fold in one study [84]. While
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spontaneous ulcers are unpredictable, traumatic ulcers may be preventable. Encouraging
patients to regularly check their skin for signs of early ulcers and preventing local trauma by
wearing properly fitting shoes and protecting themselves from insect bites may decrease the
risk of developing leg ulcers. Wearing appropriately sized above‐the‐knee compression
stockings can reduce edema and prevent new and recurrent ulcers [16].
15. Complications
15.1. Association of leg ulcers to pulmonary hypertension in adults with SCD
Evidence suggests that SCD patients with hyper‐hemolysis phenotype (characterized by
severe anemia and markers of hemolysis like high LDH) are at risk for leg ulcers as well as
pulmonary hypertension, priapism, and renal disease [115]. Studies have shown that leg ulcers
are more common in SCD patients with pulmonary hypertension [12, 116, 117]. Experts
recommend that patients with HbS with leg ulcers should be screened for pulmonary hyper‐
tension.
This epidemiological relationship between leg ulcers and pulmonary hypertension supports
a common pathophysiologic mechanism. Sickle cell patients with leg ulcers have been shown
to have higher rates of mortality that those without leg ulcers and are regarded as a marker of
disease severity in sickle cell patients [9].
15.2. Local effects
Subcutaneous fibrosis impairing venous and lymphatic drainage may occur and can be severe
enough to cause an equinus deformity [4] (Figure 4). Osteomyelitis is exceedingly rare but has
Figure 4. Leg ulcers of varying sizes (from author's personal collection).
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been observed on occasion. Acute ankle arthritis complicates some cases of spontaneous leg
ulceration, possibly as a result of associated ischemic synovial damage [118]. It resolves
spontaneously with improvement of the leg ulcer.
15.3. Social and psychological effects
Leg ulcers can have a profound impact on patients’ psychological well‐being. Patients of‐
ten have social withdrawal at school and work places. They often suffer from depression,
which may impair their ability to take care of their ulcers adequately and seek medical
attention [4].
16. Summary
In summary, sickle cell leg ulcers are a disabling complication of sickle cell disease, and despite
being widely described in the medical literature, there remains a paucity of large randomized
controlled data pertaining to their treatment. Current recommendations include a multifaceted
approach utilizing a combination of topical, systemic, and surgical techniques. We describe a
simplified algorithm to aid management of these complex patients (Figure 5). While a
multidisciplinary team is essential, it is important to retain primary responsibility of the patient
as hematologists, optimizing the health of the patient and facilitating plans of care made by
various specialties. As we begin to understand more about the complex pathophysiology of
these chronic wounds, more research is needed targeting these identified pathways to improve
ulcer healing and prevent recurrence.
Figure 5. Approach to the management of patients with SCD and wounds.
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